Biotech Investment Analyst — Drug Asset & Company Assessment

Pay: $120 - $200/hour

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.

Responsibilities

• Create and critique rubrics that analyze commercial drugs and drug-development programs

• Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers

• Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions

• Apply your assessment across the pilot's set of companies (~5–10)

Requirements

• US-based biotech / healthcare investment analyst with a specialist-fund background

• Familiarity with biotech/pharma development programs

• Able to assess a drug asset and the company behind it end-to-end

• 5+ years evaluating biotech/pharma companies or assets

Engagement Details

• Duration: Approximately 10–20 hours over a 1–2 week pilot

• Remote — US-based

Why Participate

• Help improve expert AI evaluation of drugs and drug-development programs

• Recurring engagement for strong contributors